



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Vesencumab

|           |   |
|-----------|---|
| Cat. No.: | HY-P99386   |
| CAS No.:  | 1205533-60-3  |
| Target:   | Complement System   |
| Pathway:  | Immunology/Inflammation   |
| Storage:  | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

|                           |   |
|---------------------------|---|
| Description               | Vesencumab (MNP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer <sup>[1][2]</sup> . |
| IC <sub>50</sub> & Target | neuropilin-1 <sup>[1]</sup>   |

### REFERENCES

- [1]. Jonathan Stephens, et al. Rare disease landscape: will the blockbuster model be replaced? Expert Opinion on Orphan Drugs. Volume 2, 2014 - Issue 8.
- [2]. Zhang J, et al. Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells. 2022 Oct 25;11(21):3362.
- [3]. Jonathan Stephens, et al. Rare disease landscape: will the blockbuster model be replaced? Expert Opinion on Orphan Drugs. Volume 2, 2014 - Issue 8.
- [4]. Zhang J, et al. Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells. 2022 Oct 25;11(21):3362.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA